Compare F.N.B. Corporation Common Stock (FNB) vs MiniMed Group Inc. Common Stock (MMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F.N.B. Corporation Common Stock vs MiniMed Group Inc. Common Stock — how do they compare? F.N.B. Corporation Common Stock trades at $16.91 (market cap $6.07B), while MiniMed Group Inc. Common Stock trades at $16.74 (market cap $5.18B). The key difference: F.N.B. Corporation Common Stock is the larger of the two by market cap, and F.N.B. Corporation Common Stock pays a 3.05% dividend while MiniMed Group Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold F.N.B. Corporation Common Stock for 0 Days and MiniMed Group Inc. Common Stock for 6 Days on average.
| FNB | MMED | |
|---|---|---|
Market Cap | $6.07B | $5.18B |
Volume | 5,600,609 | 33,606,669 |
Sector | Financials | Health |
52-Week High | $19.49 | $23.84 |
52-Week Low | $14.65 | $10.80 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $10.61B | $4.98B |
Dividend Yield | 3.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNB trades at $17.05, down 0.76% on the day, with a neutral technical signal. The stock shows solid fundamentals with a P/E of 10.15 and P/B of 0.89, indicating potential undervaluation. Recent earnings have been mixed, with Q2 2026 beating estimates but Q1 missing. Revenue remains stable at $1.77 billion for 2025, with a strong net income margin of 33.04%. Analyst sentiment is positive, with 13 buy ratings and a consensus price target of $20.80.
The outlook for FNB is cautiously optimistic, supported by strong profitability and a favorable analyst consensus. Key opportunities include potential upside to the price target and consistent dividend payments. Risks involve earnings volatility, as seen in recent quarters, and competitive pressures in the banking sector. Investors should weigh the attractive valuation against execution risks and market conditions.
MMED trades at $18.40, down 2.13% today, with technical indicators showing bearish momentum. The company reported revenue growth to $2.72B in 2025 but posted a net loss of -$250M. Recent news highlights Medtronic's exchange offer completion and MiniMed's new product launches. Analyst consensus remains strongly bullish with 100% buy ratings and a $25.73 price target, representing 40% upside potential from current levels.
Despite negative profitability metrics and bearish technical signals, MMED maintains strong analyst support and revenue growth trajectory. Key risks include persistent net losses, high short interest, and execution challenges in the competitive diabetes technology market. The stock offers potential upside if new product cycles drive margin improvement and profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About F.N.B. Corporation Common Stock
F.N.B. Corporation is a diversified financial services holding company headquartered in Pittsburgh, Pennsylvania, operating through its lead subsidiary, First National Bank of Pennsylvania. It provides commercial banking, consumer banking, wealth management, and insurance through more than 350 banking offices across seven states and Washington, D.C.
Read more on FNB →About MiniMed Group Inc. Common Stock
MiniMed develops, manufactures, and markets diabetes-management technologies. Its products include insulin-delivery systems, continuous glucose monitors, smart insulin pens, and related software.
Read more on MMED →
